AMPK inhibition enhances apoptosis in MLL-rearranged pediatric B-acute lymphoblastic leukemia cells

B. Accordi, L. Galla, G. Milani, M. Curtarello, V. Serafin, V. Lissandron, G. Viola, G. Te Kronnie, R. De Maria, E. F. Petricoin, L. A. Liotta, S. Indraccolo, G. Basso

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The serine/threonine kinase AMP-activated protein kinase (AMPK) and its downstream effectors, including endothelial nitric oxide synthase and BCL-2, are hyperactivated in B-cell precursor-acute lymphoblastic leukemia (BCP-ALL) cells with MLL gene rearrangements. We investigated the role of activated AMPK in supporting leukemic cell survival and evaluated AMPK as a potential drug target. Exposure of leukemic cells to the commercial AMPK inhibitor compound C resulted in massive apoptosis only in cells with MLL gene rearrangements. These results were confirmed by targeting AMPK with specific short hairpin RNAs. Compound C-induced apoptosis was associated with mitochondrial membrane depolarization, reactive oxygen species production, cytochrome c release and caspases cleavage, indicating intrinsic apoptosis pathway activation. Treatment with low concentrations of compound C resulted in a strong antileukemic activity, together with cytochrome c release and cleavage of caspases and poly(ADP-ribose) polymerase, also in MLL-rearranged primary BCP-ALL samples. Moreover, AMPK inhibition in MLL-rearranged cell lines synergistically enhanced the antiproliferative effects of vincristine, daunorubicin, cytarabine, dexamethasone and L-asparaginase in most of the evaluated conditions. Taken together, these results indicate that the activation of the AMPK pathway directly contributes to the survival of MLL-rearranged BCP-ALL cells and AMPK inhibitors could represent a new therapeutic strategy for this high-risk leukemia.

Original languageEnglish
Pages (from-to)1019-1027
Number of pages9
JournalLeukemia
Volume27
Issue number5
DOIs
Publication statusPublished - May 2013

Fingerprint

AMP-Activated Protein Kinases
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pediatrics
Apoptosis
B-Lymphoid Precursor Cells
Gene Rearrangement
Protein Kinase Inhibitors
Caspases
Cytochromes c
Asparaginase
Daunorubicin
Poly(ADP-ribose) Polymerases
Nitric Oxide Synthase Type III
Protein-Serine-Threonine Kinases
Cytarabine
Mitochondrial Membranes
Vincristine
Dexamethasone
Small Interfering RNA
Reactive Oxygen Species

Keywords

  • acute lymphoblastic leukemia
  • AMPK
  • apoptosis
  • MLL rearrangements

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Accordi, B., Galla, L., Milani, G., Curtarello, M., Serafin, V., Lissandron, V., ... Basso, G. (2013). AMPK inhibition enhances apoptosis in MLL-rearranged pediatric B-acute lymphoblastic leukemia cells. Leukemia, 27(5), 1019-1027. https://doi.org/10.1038/leu.2012.338

AMPK inhibition enhances apoptosis in MLL-rearranged pediatric B-acute lymphoblastic leukemia cells. / Accordi, B.; Galla, L.; Milani, G.; Curtarello, M.; Serafin, V.; Lissandron, V.; Viola, G.; Te Kronnie, G.; De Maria, R.; Petricoin, E. F.; Liotta, L. A.; Indraccolo, S.; Basso, G.

In: Leukemia, Vol. 27, No. 5, 05.2013, p. 1019-1027.

Research output: Contribution to journalArticle

Accordi, B, Galla, L, Milani, G, Curtarello, M, Serafin, V, Lissandron, V, Viola, G, Te Kronnie, G, De Maria, R, Petricoin, EF, Liotta, LA, Indraccolo, S & Basso, G 2013, 'AMPK inhibition enhances apoptosis in MLL-rearranged pediatric B-acute lymphoblastic leukemia cells', Leukemia, vol. 27, no. 5, pp. 1019-1027. https://doi.org/10.1038/leu.2012.338
Accordi, B. ; Galla, L. ; Milani, G. ; Curtarello, M. ; Serafin, V. ; Lissandron, V. ; Viola, G. ; Te Kronnie, G. ; De Maria, R. ; Petricoin, E. F. ; Liotta, L. A. ; Indraccolo, S. ; Basso, G. / AMPK inhibition enhances apoptosis in MLL-rearranged pediatric B-acute lymphoblastic leukemia cells. In: Leukemia. 2013 ; Vol. 27, No. 5. pp. 1019-1027.
@article{92fbfa4ec42a4819a9e2245d08cca619,
title = "AMPK inhibition enhances apoptosis in MLL-rearranged pediatric B-acute lymphoblastic leukemia cells",
abstract = "The serine/threonine kinase AMP-activated protein kinase (AMPK) and its downstream effectors, including endothelial nitric oxide synthase and BCL-2, are hyperactivated in B-cell precursor-acute lymphoblastic leukemia (BCP-ALL) cells with MLL gene rearrangements. We investigated the role of activated AMPK in supporting leukemic cell survival and evaluated AMPK as a potential drug target. Exposure of leukemic cells to the commercial AMPK inhibitor compound C resulted in massive apoptosis only in cells with MLL gene rearrangements. These results were confirmed by targeting AMPK with specific short hairpin RNAs. Compound C-induced apoptosis was associated with mitochondrial membrane depolarization, reactive oxygen species production, cytochrome c release and caspases cleavage, indicating intrinsic apoptosis pathway activation. Treatment with low concentrations of compound C resulted in a strong antileukemic activity, together with cytochrome c release and cleavage of caspases and poly(ADP-ribose) polymerase, also in MLL-rearranged primary BCP-ALL samples. Moreover, AMPK inhibition in MLL-rearranged cell lines synergistically enhanced the antiproliferative effects of vincristine, daunorubicin, cytarabine, dexamethasone and L-asparaginase in most of the evaluated conditions. Taken together, these results indicate that the activation of the AMPK pathway directly contributes to the survival of MLL-rearranged BCP-ALL cells and AMPK inhibitors could represent a new therapeutic strategy for this high-risk leukemia.",
keywords = "acute lymphoblastic leukemia, AMPK, apoptosis, MLL rearrangements",
author = "B. Accordi and L. Galla and G. Milani and M. Curtarello and V. Serafin and V. Lissandron and G. Viola and {Te Kronnie}, G. and {De Maria}, R. and Petricoin, {E. F.} and Liotta, {L. A.} and S. Indraccolo and G. Basso",
year = "2013",
month = "5",
doi = "10.1038/leu.2012.338",
language = "English",
volume = "27",
pages = "1019--1027",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - AMPK inhibition enhances apoptosis in MLL-rearranged pediatric B-acute lymphoblastic leukemia cells

AU - Accordi, B.

AU - Galla, L.

AU - Milani, G.

AU - Curtarello, M.

AU - Serafin, V.

AU - Lissandron, V.

AU - Viola, G.

AU - Te Kronnie, G.

AU - De Maria, R.

AU - Petricoin, E. F.

AU - Liotta, L. A.

AU - Indraccolo, S.

AU - Basso, G.

PY - 2013/5

Y1 - 2013/5

N2 - The serine/threonine kinase AMP-activated protein kinase (AMPK) and its downstream effectors, including endothelial nitric oxide synthase and BCL-2, are hyperactivated in B-cell precursor-acute lymphoblastic leukemia (BCP-ALL) cells with MLL gene rearrangements. We investigated the role of activated AMPK in supporting leukemic cell survival and evaluated AMPK as a potential drug target. Exposure of leukemic cells to the commercial AMPK inhibitor compound C resulted in massive apoptosis only in cells with MLL gene rearrangements. These results were confirmed by targeting AMPK with specific short hairpin RNAs. Compound C-induced apoptosis was associated with mitochondrial membrane depolarization, reactive oxygen species production, cytochrome c release and caspases cleavage, indicating intrinsic apoptosis pathway activation. Treatment with low concentrations of compound C resulted in a strong antileukemic activity, together with cytochrome c release and cleavage of caspases and poly(ADP-ribose) polymerase, also in MLL-rearranged primary BCP-ALL samples. Moreover, AMPK inhibition in MLL-rearranged cell lines synergistically enhanced the antiproliferative effects of vincristine, daunorubicin, cytarabine, dexamethasone and L-asparaginase in most of the evaluated conditions. Taken together, these results indicate that the activation of the AMPK pathway directly contributes to the survival of MLL-rearranged BCP-ALL cells and AMPK inhibitors could represent a new therapeutic strategy for this high-risk leukemia.

AB - The serine/threonine kinase AMP-activated protein kinase (AMPK) and its downstream effectors, including endothelial nitric oxide synthase and BCL-2, are hyperactivated in B-cell precursor-acute lymphoblastic leukemia (BCP-ALL) cells with MLL gene rearrangements. We investigated the role of activated AMPK in supporting leukemic cell survival and evaluated AMPK as a potential drug target. Exposure of leukemic cells to the commercial AMPK inhibitor compound C resulted in massive apoptosis only in cells with MLL gene rearrangements. These results were confirmed by targeting AMPK with specific short hairpin RNAs. Compound C-induced apoptosis was associated with mitochondrial membrane depolarization, reactive oxygen species production, cytochrome c release and caspases cleavage, indicating intrinsic apoptosis pathway activation. Treatment with low concentrations of compound C resulted in a strong antileukemic activity, together with cytochrome c release and cleavage of caspases and poly(ADP-ribose) polymerase, also in MLL-rearranged primary BCP-ALL samples. Moreover, AMPK inhibition in MLL-rearranged cell lines synergistically enhanced the antiproliferative effects of vincristine, daunorubicin, cytarabine, dexamethasone and L-asparaginase in most of the evaluated conditions. Taken together, these results indicate that the activation of the AMPK pathway directly contributes to the survival of MLL-rearranged BCP-ALL cells and AMPK inhibitors could represent a new therapeutic strategy for this high-risk leukemia.

KW - acute lymphoblastic leukemia

KW - AMPK

KW - apoptosis

KW - MLL rearrangements

UR - http://www.scopus.com/inward/record.url?scp=84877614687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877614687&partnerID=8YFLogxK

U2 - 10.1038/leu.2012.338

DO - 10.1038/leu.2012.338

M3 - Article

C2 - 23228943

AN - SCOPUS:84877614687

VL - 27

SP - 1019

EP - 1027

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 5

ER -